Back to News
Market Impact: 0.15
Arvinas' ARV-102 Shows Biomarker Changes In Parkinson's Phase 1 Trial
Source: Nasdaq
Healthcare & Biotech
Arvinas reported new Phase 1 data for ARV-102, an investigational oral PROTAC degrader designed to target and degrade LRRK2 in patients with Parkinson's disease. The report provides no specific results or safety findings, so the data's clinical significance cannot be assessed from the article.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
ARVN0.30
More News
- Profound Medical stock surges 20% on raised Q3 revenue outlook
- Halozyme stock rises after winning injunction against Merck
- Medical device maker Centinel Spine discloses revenue rise in US IPO filing
- BTIG cuts ArriVent BioPharma stock price target on trial results
- MustGrow Biologics at 20th iif: sales grow as Bayer backs pipeline
- Healthcare Services Group acquires NEXDINE Hospitality for $93.5M